4 withdrawn. 4 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 4 | Withdrawn 4 |
| Phase 2 | 2 | Withdrawn 2 |
Follow Primary Immunodeficiency Diseases: new trials by email Literature Review of Primary Immunodeficiency Diseases trials Research Report on Primary Immunodeficiency Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of GNR-038 vs Berinert® in Patients With Hereditary Angioedema GNR-038, 50 МЕ/ kg, GNR-038, 100 МЕ/ kg, Berinert®, 20 МЕ/ kg - Hereditary Angioedema | Phase 2 / Phase 3 | Withdrawn | AO GENERIUM | 2021-12-01 | 2022-02-04 | |
| Study Evaluating IGSC 20% Flexible Dosing in Treatment-Experienced and Treatment-Naive Subjects With Primary Immunodeficiency IGSC 20% daily push versus every 2 weeks pump, IGSC 20% daily push versus once a week pump, IGSC 20% daily push versus 2 times per week pump - Primary Immunodeficiency | Phase 3 | Withdrawn | Grifols Therapeutics LLC | 2019-12-01 | 2020-04-10 | |
| Study of Immune Globulin Intravenous (Human) GC5101F in Subjects With Primary Humoral Immunodeficiency Immunoglobulin - Primary Immune Deficiency Disorder | Phase 3 | Withdrawn | Green Cross Corporation | 2019-04-30 | 2020-07-07 | |
| Study to Evaluate Ecallantide in Paediatric Patients With Acute Attacks of Hereditary Angioedema ecallantide - Hereditary Angioedema (HAE) | Phase 2 / Phase 3 | Withdrawn | Shire | 2012-06-01 | 2021-05-18 |
Angioedemas, Hereditary (2) · Angioedema (1) · Genetic Diseases, Inborn (1) · Hypersensitivity (1) · Immune System Diseases (1)
Congenital, Hereditary, and Neonatal Diseases and Abnormalities (4) · Immunologic Deficiency Syndromes (4) · Genetic Diseases, Inborn (3) · Immune System Diseases (3) · Cardiovascular Diseases (2) · Hereditary Complement Deficiency Diseases (2) · Hypersensitivity, Immediate (2) · Skin Diseases (2) · Skin Diseases, Vascular (2) · Skin and Connective Tissue Diseases (2) · Urticaria (2) · Vascular Diseases (2) · Angioedema (1) · Hypersensitivity (1)
Complement C1 Inhibitor Protein (1) · Immunoglobulins (1) · ecallantide (1)
AO GENERIUM (1) · Green Cross Corporation (1) · Grifols Therapeutics LLC (1) · Shire (1)
Russia (1) · United States (1)
Chaim Roifman (1) · Oksana A. Markova, MD (1)